In this study, blood biomarkers, such as SAA (an inflammatory biomarker, a precursor of beta-amyloid plaques in the brain), Hcy (a pro-inflammatory molecule increased in cognitive disorders), S100B (a neuronal structural protein increased in brain injury), and BDNF (decreased in cognitive disorders) were selected in order to validate the hypothesis that these biomarkers could be used as predictive factors for cognitive impairment associated with IBD. Here, S100B is linked to cognitive disorder.